PT-141
PT-141 (10 mg), also known as bremelanotide, is a synthetic melanocortin receptor agonist peptide derived from melanocortin analog research. It is primarily investigated for its interaction with melanocortin receptor subtypes in controlled laboratory environments.
PT-141 is being studied for its central melanocortin receptor activity, with a focus on its effects at MC3R and MC4R. These receptors are involved in neuroendocrine and hypothalamic signaling networks, rather than direct peripheral vasodilatory mechanisms. Because of this, PT-141 is often used in experimental models exploring peptide-mediated communication between the central nervous system and endocrine pathways.
The 10 mg format is supplied as a lyophilized powder to support handling and reconstitution for in vitro and preclinical studies.
Key Research Areas
In Women: FDA-approved (as Vyleesi) to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
In Men: Studied off-label for erectile dysfunction (ED), particularly for patients unresponsive to PDE5 inhibitors.
BAC WATER SOLD SEPARATELY
PRODUCT SPECIFICATIONS
CAS Number: 189691-06-3
Peptide Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Molecular Weight: 1025.182 g/mol
Subcategory: Sexual Health & Hormonal Peptides
Purity: ≥95% (verified by HPLC)
Packaging Format: 10 mg lyophilized powder in sealed research-grade vial
Storage Conditions: Store at 2–8 °C or frozen at ≤ –20 °C as appropriate. Protect from light and moisture. Minimize room-temperature exposure.
Intended Use: For Laboratory Research Use Only
